Coffee Consumption and Improved Colorectal Cancer Survivorship: From Observational to Interventional Studies
Observational findings from several independent cohorts have consistently shown a beneficial association of coffee consumption after diagnosis with better survival outcomes among patients with colorectal cancer. In support of these data, coffee has been linked to lower risk of metabolic disorders, lower inflammation, and favorable blood biochemical profiles. While the components in coffee that drive these benefits remain unknown, studies of metabolomics and microbiome have identified potential molecules and mechanisms of action underlying coffee's beneficial effects. These data altogether have motivated the conduct of the first randomized control trial of coffee consumption among colorectal cancer survivors (the COMMENCER trial). In this presentation, Dr. Song will review the existing data, present the COMMENCER trial, and discuss the future directions.
Target Audience
- Physicians
- Residents
- Medical Students
- Pharmacists
- Physician assistants
- Nurses
- Other Healthcare Professionals
Learning Objectives
- Aware of preliminary findings and lessons learned from a randomized trial in colon cancer survivors (COMMENCER), along with opportunities for integrating specific food/beverages and overall nutrition principles into oncology care.
Introduction and background context on colon cancer, dietary/beverage consumption patterns, and biological underpinning of research in this field
Presentation of observational findings from several independent cohorts showing association of coffee consumption after diagnosis with better survival outcomes among patients with colorectal cancer.
Presentation of evidence on association between coffee and lower risk of metabolic disorders, lower inflammation, and favorable blood biochemical profiles.
Discussion of possible mechanisms: unknown, but studies of metabolomics and microbiome have identified potential molecules and mechanisms of action underlying coffee's beneficial effects.
Presentation of the COMMENCER trial - first randomized control trial of coffee consumption among colorectal cancer survivors
Review of existing data and discussion of future directions
Q&A and discussion with audience
- Email: Your CME Certificate to Physician Education & CME at [email protected].
- Online: Via the CME Self-Reporting Tool (login required).
Available Credit
- 1.00 AMA PRA Category 1 Credit™The George Washington University School of Medicine and Health Sciences is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
- 1.00 Completion
Registration Instructions
Please note that you must be logged in to complete the CE credit claim process.
New Users
You must create a learner account prior to claiming CE credit.
Click here to create a learner account
Click here to access additional instructions for creating a learner account

Facebook
X
LinkedIn
Forward